Microbes are unique creatures that adapt to varying lifestyles and environment resistance in
extreme or adverse conditions. The genetic architecture of microbe may bear a significant …

There are very few drug delivery systems that target key organs via the oral route, as oral
delivery advances normally address gastrointestinal drug dissolution, permeation, and …

Infections caused by Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp.,
Entamoeba histolytica, Giardia lamblia, Plasmodium spp., and Trichomonas vaginalis, are …

Herein, we demonstrate a solvent-free mechanochemical approach involving a one-pot-
double-step procedure mediated by solid sodium hypochlorite (NaOCl· 5H2O) for the …

Amphotericin B (AmB) has a broad antifungal and leishmanicidal activity with low incidence
of clinical resistance. Its parenteral administration has high risk of nephrotoxiciy that limits its …

The incidence of fungal pulmonary infections is known to be on the increase, and yet there is
an alarming gap in terms of marketed antifungal therapies that are available for pulmonary …

Nanoenabled lipid-based drug delivery systems offer a platform to overcome challenges
encountered with current failed leads in the treatment of parasitic and infectious diseases …

Continuing with our efforts to identify new active compounds against malaria and
leishmaniasis, 14 new 3-amino-1, 4-di-N-oxide quinoxaline-2-carbonitrile derivatives were …

Leishmaniasis is a neglected disease presenting cutaneous, mucosal and visceral forms
and affecting an estimated 12 million mostly low-income people. Treatment of cutaneous …

Cutaneous fungal and parasitic diseases remain challenging to treat, as available therapies
are unable to permeate the skin barrier. Thus, treatment options rely on systemic therapy …